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SARS-CoV-2 has spread rapidly worldwide, but the full impact of the COVID-19 pandemic on the field of hematopoietic
cell transplantation (HCT) remains unknown. To understand this better, an 18-item online surveywas disseminated by
the Worldwide Network for Blood & Marrow Transplantation with questions exploring SARS-CoV-2 testing algo-
rithms, mobilization, and cryopreservation strategies and COVID-19 infections in allogeneic related and autologous
hematopoietic progenitor cell (HPC) donors. The aim of this survey was to assess the impact of the outbreak on policies
relating to HPCmobilization, collection, and processingwith respect to changes in daily routine. A total of 91 individual
responses from distinct centers in 6 continents were available for analysis. In these centers, the majority (72%) of allo-
geneic related and autologous donors are routinely tested for SARS-CoV-2 before HPC collection, and 80% of centers
implement cryopreservation of allogeneic HPC grafts before commencing conditioning regimens in patients. Five
related and 14 autologous donors who tested positive for COVID-19 did not experience any unexpected adverse events
or reactions during growth factor administration (eg, hyperinflammatory syndrome). These data are limited by the
small number of survey respondents but nonetheless suggest that centers are following the recommendations of
appropriate scientific organizations and provide some preliminary data to suggest areas of further study.
© 2020 The American Society for Transplantation and Cellular Therapy. This is an open access article under the CC BY-
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In late 2019, a novel coronavirus, later named severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in
China and then spread worldwide, causing the disease called
coronavirus disease 2019 (COVID-19). On March 11, 2020, the
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pandemic. Subsequently, many countries imposed major
restrictions on travel and everyday life and were in a state of
“lockdown.” At the time of this writing (October 30, 2020),
more than 46 million global cases, 1,195,418 global deaths,
and 565,797 new daily cases have been reported by the WHO
and Johns Hopkins University [1,2]. COVID-19 continues to
have a significant impact on all aspects of hematopoietic cell
transplantation (HCT) in many parts of the world and will
likely impact the future use of cellular therapies, including chi-
meric antigen receptor T (CAR T) cell therapy.
Early in the outbreak, scientific and not-for profit organiza-
tions, including the European Society for Blood and Marrow
Transplantation (EBMT) [3], the American Society for Transplan-
tation and Cellular Therapies (ASCT), the Center for International
Blood and Marrow Transplant Research (CIBMTR) [4], and the
World Marrow Donor Association (WMDA) [5], developed rec-
ommendations for HCT centers and hematopoietic progenitor
cell (HPC) collection and processing facilities. These recommen-
dations are updated regularly and include preventive measures
for staff and outpatient visits [6,7]. In addition, the Worldwide
Network for Blood & Marrow Transplantation (WBMT), a non-
profit organization in a official relationship with the WHO, has
recommended deferring nonurgent HCT in areas with endemic
or highfrequency COVID19 infection [8]. More recently, a con-
sensus decision was reached between the WBMT and CIBMTR’s
Health Services and International Studies (HSIS) committee and
other HCT experts representing multiple continents [9]. Later,
concerns about the use of granulocyte colony-stimulating factor
(G-CSF) products in SARS-CoV-2-infected individuals and the
potential for induction of adverse events, such as hyperinflam-
matory reactions, were raised.
To better understand the impact of the pandemic on trans-
plantation centers, a survey was disseminated by the WBMT
with questions exploring SARS-CoV-2 testing algorithms,
mobilization and cryopreservation strategies, and COVID-19
infections in allogeneic related and autologous hematopoietic
progenitor cell (HPC) donors. As accumulating evidence sug-
gests that a subgroup of patients with severe COVID-19 may
experience a cytokine storm syndrome, we were also inter-
ested to explore whether G-CSF administration as part of HPC
mobilization would be able to cause a hyperinflammatory
state, including secondary hemophagocytic lymphohistiocyto-
sis, in cases of COVID-19 positivity.
METHODS
A link to a survey using the SurveyGizmo tool (SurveyGizmo, Boulder, CO)
was disseminated by the WBMT to member societies the Australasian Bone Mar-
row Transplant Recipient Registry (ABMTRR), African Blood and Marrow Trans-
plantation Society, Asia Pacific Blood and Marrow Transplantation Group
(APBMT), ASTCT, CIBMTR, EBMT, Eastern Mediterranean Blood and Marrow
Transplantation Group (EMBMT), and Latin America Blood and Marrow Trans-
plantation Group (LABMT), who were asked to invite their members to partici-
pate. The decision to circulate the survey and how this was done was specific to
each member organization. A reminder was requested to be sent out around 1
week after dissemination. The survey was available online for 3 weeks. Not all the
organizations were able to disseminate the invitation to members in the time-
frame of the study. In view of the nature of the participating organizations, some
have overlapping membership. Only one completed survey per center (the most
complete) was accepted after review by theWBMT office.
SURVEY
The 18-item survey (“SARS-CoV-2 in related donors and
patients after G-CSF mobilization”) was developed by the
standing Committee on Donor Issues of the WBMT and the
WBMT Board and transferred to SurveyGizmo (Supplementary
Table S1). The authors piloted the survey, assessed the design,
and checked the feasibility and validity of the questions. Thefinalized online survey was made available online from May
18 to June 8, 2020.
We sought agreement to publish the compiled data and for
descriptive data of the respective centers (ie, country, city, cen-
ter name, society for outcome data reporting, center number,
and contact person). The following points were addressed in
patients with allogeneic related donors: SARS-CoV-2 testing
policy, test results, severe events and adverse reaction to G-
CSF administration, clinical outcome in those tested positive,
and policies for collection and processing of allogeneic prod-
ucts. Patients undergoing autologous mobilization were
assessed for SARS-CoV-2 testing and test results in those
undergoing HPC mobilization, severe events and adverse reac-
tion to G-CSF administration and clinical outcome in those
testing positive, and possible changes in mobilization strate-
gies during the COVID-19 pandemic in the autologous setting
(Supplementary Table S1).
To explore whether G-CSF administration and concurrent
COVID-19 infection resulted in a hyperinflammatory syn-
drome, we asked specific questions were asked about elevated
levels of C-reactive protein (CRP), lactate dehydrogenase
(LDH), D-dimer, and ferritin. We also collected data on the
need for intensive care, mechanical ventilation, and dialysis.RESULTS
A total of 153 individual responses was received.We accepted
only one response per center and deleted duplicates and blank
responses. After data cleaning, 91 responses remained for further
analysis. The responding countries and number of centers are
listed in Supplementary Table S2. Answers reflect the policies
and possibilities (in terms of resources) of centers in different
parts of the world at the time of the survey.
The majority of responding centers routinely report their HCT
outcome data to the CIBMTR (n = 50; 55%) and EBMT (n = 26;
29%). In addition, 5% of centers (n = 4) report to the EMBMT, 3%
(n = 3) report to the LABMT, 1% (n = 1) report to the APBMT, and
8% (n = 7) report to other organizations not specified.
Allogeneic Donors
SARS-CoV-2 Testing in Related Donors
The majority of responding centers (73%; 66 of 91) reported
always testing related donors since the pandemic, whereas
17% (16 of 91) tested only on request of the transplantation/
apheresis center, and 9 (10%) did not have the ability to test at
all. Centers not having the ability to test at the time of the sur-
vey (late May to June 2020) were located in Brazil (n = 3), Thai-
land (n = 1), and the United States (n = 5). Testing on request
was possible in centers located in Algeria (n = 1), Australia
(n = 2), Brazil (n = 1), Canada (n = 2), China (n = 1), India
(n = 2), Israel (n = 1), Saudi Arabia (n = 1), and the United States
(n = 5).
Regarding the time point of SARS-CoV-2 testing, the follow-
ing options were given in the survey, and participants could
choose one or more applicable options: at medical checkup, at
the start of mobilization (ie, 1 to 3 days before or at the day of
the first G-CSF application), on the day of collection, and only
in the event of symptoms. Twenty-four percent (16 of 66)
reported testing allogeneic donors at medical checkup. How-
ever, 9 of these centers repeat the test when starting the mobi-
lization regimen. Therefore, the majority (86%) of responding
centers tested related donors at the start of mobilization.
Seven centers (11%) also tested on the day of collection. Five
percent of centers reported testing only in the event of symp-
toms or in donors at risk of SARS-CoV-2 infection. (Figure 1A).
Figure 1. The algorithm for SARS-CoV-2 testing in allogeneic related (n = 91) (A) and autologous (n = 90) (B) HPC donors. 1A. allogeneic donors (91 centers reported
data).
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Sixty-six of the 91 responding centers answered this ques-
tion. Four of 66 centers reported a total of 5 donors testing pos-
itive at medical checkup (n = 1), start of mobilization (n = 2),
collection (n = 1), or at follow-up (n = 1 on day 18 after dona-
tion). The donors were reported from 2 different centers in
Brazil (1 donor each), 1 center in Italy (2 donors), and 1 centerin the United States (1 donor). No detailed information on the
deferral period of the donors who tested positive at medical
checkup was given. All but 1 center reported cryopreserving
related and unrelated allogeneic HPCs, whereas the Italian
center reported freezing only unrelated HPCs. For this reason,
this center had to use the HPCs even though the donor had
tested positive.
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from COVID-19 positive tested donors, we contacted the
reporting centers, but were not successful in gaining more
information. In the 3 positive donors who received G-CSF con-
currently during their COVID-19 infection, no adverse events
after G-CSF mobilization or hyperinflammatory symptoms
were noted. In 2 cases where CRP, LDH, and D-dimer levels
were tested, values were within the normal ranges, but these
tests were not done in the remaining 3 donors. Ferritin level
was available in only 1 donor who tested positive on day 18
after HPC donation and was elevated. The clinical course was
uneventful in 4 donors, whereas only 1 donor who experi-
enced the infection on day 18 after HPC donation presented
with fever for 3 days. None of these donors required hospital
admission.
Further information on the outcome of 3 patients who
received products from donors tested positive at medical
checkup (n = 1), at the start of mobilization (n = 1), and during
follow-up (n = 1 on day 18 after donation) was provided by the
respective centers. In none of the 3 patients was transmission
of SARS-CoV-2 detected. Data from the remaining 2 patients
have not been reported.
Changes to Centers’ Policies for Handling Allogeneic HPC Grafts
During the SARS-CoV-2 Pandemic
The majority of centers (75%; 68 of 91) changed their poli-
cies with regard to allogeneic HCT. Fifteen of these centers
(22%) reported proceeding to HCT only for patients with high-
risk disease while delaying HCT for those without urgent
transplant indications, in accordance with recommendations
of the EBMT and ASTCT. In addition, participating centers
reported using peripheral blood stem cells more often than
bone marrow during that time and in 5 of 68 centers (7%), a
switch to haploidentical family donors instead of unrelated
donors was considered.
Fifty percent of centers began cryopreserving allogeneic
HPC products (peripheral blood stem cells and bone marrow)
from related and unrelated donors before starting a condition-
ing regimen. Twenty-six percent cryopreserve products only
from unrelated donors, whereas 4% do so only from related
donors. Eighteen centers (20%) reported not freezing alloge-
neic products.
In 43% of centers, a negative SARS-CoV-2 test in the donor
is required for further release of the stem cell product. Forty-
three percent of centers wait for a negative medical history of
the donor 1 to 2 weeks after donation, whereas 24% do not
have any new requirements.
Autologous Donors
Ninety centers responded to survey items for autologous
donors.
Centers Changing Their Mobilization Policy for Autologous HPC
Grafts During the SARS-CoV-2 Pandemic
The majority of centers (73%; 66 of 90) changed their mobi-
lization policy for autologous HPCs, whereas 7 centers (2 in
Australia and 1 each in Brazil, India, Kuwait, Pakistan, and
Thailand) reported stopping autologous HPC collection at the
time the survey was conducted. The responses from 82 of the
90 centers (91%) were available for more detailed analysis:
19% answered that they used chemotherapy-based mobiliza-
tion for all patients and 33% did so only for patients with stan-
dard protocols for their underlying disease (eg, diffuse large
cell lymphoma, Hodgkin lymphoma), whereas the majority
(48%) used steady-state G-CSF mobilization for all patients.SARS-CoV-2 Testing in Patients Undergoing Autologous HPC
Mobilization
At the time of the survey, the majority of centers (72%)
tested all patients before HPC mobilization, whereas 6% tested
only before chemotherapy-based mobilization, 18% never
tested, and 4% reported being unable to test. The latter centers
were in Brazil (n = 3) and Canada (n = 1) (Figure 1).
Patients Undergoing HPC Mobilization Who Tested Positive for
SARS-CoV-2 and Clinical Course
Nine of the 90 centers (10%; Austria, n = 1; Brazil, n = 4;
Kuwait, n = 1; Turkey, n = 1; United States, n = 2) reported a
total of 14 patients testing positive for SARS-CoV-2 during the
mobilization/collection period. Nine patients were reported
from the 4 Brazilian centers, and the other centers each had
only 1 patient detected with a COVID-19 infection.
In no case infection with SARS-CoV-19 was associated with
additional adverse events to G-CSF mobilization and none of
the patients presented with a hyperinflammatory state.
Detailed laboratory parameters were made available for 12
patients. In the majority, elevated levels of CRP (n = 16), ferritin
(n = 7), and D-dimer (n = 6) were observed. One patient was
admitted to an intensive care unit, but mechanical ventilation
or dialysis was not required.
Data on the duration of symptoms and admission were
available for 9 patients. In 6 of these patients, the infection
was clinically asymptomatic despite abnormal laboratory
parameters. Three patients had clinical symptoms over 7 to
8 days leading to hospital admission for 10 days in 2 of them.
Data on the duration of infection and need for hospitalization
were not reported in 5 patients.
The clinical outcome was available for 13 patients. One
patient died due to COVID-19 infection, while 12 recovered
without complications.
Seven of the 9 centers reported not using HPC products col-
lected from SARS-CoV-2- positive patients. One center
reported testing the product before using it for HPC transplan-
tation, whereas another center reported using the product.
DISCUSSION
This is the first survey not only to address changes in the
daily practice of autologous and allogeneic HPC collection and
processing units, and transplant centers during the pandemic
and lock-down of the respective countries but also to analyze
whether SARS-CoV-2 infections may have an influence on the
tolerability of G-CSF administration for HPC mobilization
either as single-agent therapy or in combination with chemo-
therapy.
Key Results
The majority of centers changed their policy and began to
order products especially from unrelated donors in advance.
This was not only due to the local COVID-19 situation, but also
to the situation in the respective region of the collection cen-
ters, as travel restrictions made it impossible to foresee
whether a product will arrive in time. Interestingly, countries
not freezing allogeneic products at the time of the survey (ie,
Algeria, Brazil, China, Jordan, Lebanon, Mexico, Oman, Paki-
stan, Paraguay, Saudi Arabia, and Hawaii) were mostly in the
early stages of a marked increase of COVID-19 cases (Brazil,
Mexico, Oman, Pakistan, and Saudi Arabia) or had only a very
low daily infection rate (eg, Algeria, <100/day; Jordan and
Hawaii, <20/day; Paraguay, <30/day; Lebanon, <50/day).
In accordance with published recommendations of scien-
tific societies (eg, ASTCT, EBMT) for recipients and donors of
Figure 2. Outbreak evolution for the 10 most affected countries in the world (as of October 30, 2020), according to the Johns Hopkins University Coronavirus
Resource Center. The dashed bar indicates the survey period (May 18 to June 8, 2020).
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more urgent transplantation indications while postponing
non-urgent transplantations.
Few COVID-19 cases have been reported in allogeneic
related HPC donors. In these donors, no increase in severe
events and adverse reactions due to growth factor mobiliza-
tion was observed. Available data in 3 recipients of HPC grafts
from SARS-CoV-2-positive donors demonstrated no viral
transmission. Similar to other human coronaviruses (including
SARSCoV and MERSCoV), transfusion transmission of
SARSCoV2 has not yet been reported, suggesting that trans-
fusion transmission of coronaviruses is rare if it occurs at all.
However, it is acknowledged that SARSCoV2 has been iden-
tified only recently, and thus the possibility of virus transmis-
sion by transfusion cannot be excluded [10-13].
More infections were observed in autologous cases, unfor-
tunately also with 1 fatal outcome, but no increased severe
events and adverse reactions due to G-CSF or hyperinflamma-
tion were reported in this group. Recent studies have identi-
fied cancer patients as a vulnerable population with a high risk
of morbidity due to COVID-19 [14-17]; however, published
case fatality rates vary widely (62% vs 13%), depending also on
patient age and comorbidities [14-18].
Limitations
This survey has several limitations. One limitation is that it
mirrors strategies of responding centers only for the survey
period fromMay to June 2020. However, we were able to include
91 responses and reach centers in 6 continents (Africa, Asia, Aus-
tralia, Europe, North America, and South America). Moreover, the
number of centers responding to our survey varied among coun-
tries. Therefore, our data reflect only components of the situation
in different countries and cannot be generalized for whole coun-
tries or whole continents. The invitation and link to the survey
was disseminated by WBMT to all the member societies,
although the invitation was not disseminated by all member
societies to their members, and thus European countries and cen-
ters are underrepresented in this survey.
The survey was sent out shortly after the peak of COVID-19
infections in Europe and Turkey, but at that time infections
were dramatically increasing in North and South America, theNear East, and Africa. Contemporary infection rates in Canada
had declined already and were in between 2 peaks in Australia,
Europe and the Middle East (Figure 2). This implies that conti-
nents and the regional responses may have been affected by
the pandemic to varying degrees. Depending on the location of
centers and the COVID-19 situation in the respective region,
recommendations of associated scientific organizations were
followed [4,6-9].
To prevent exposure to COVID-19 in patients and donors,
especially in regions where testing is not possible, it is recom-
mended that maximum emphasis be placed on personal pro-
tection by avoiding unnecessary travel to highrisk areas and
exercising good hygiene for donors and patients. Even though
this virus has not been shown to be transmitted by transfusion
of blood products, published recommendations for donor
screening and detailed medical history (including travel his-
tory, exposure to COVID-19, etc) should be included in all cen-
ters’ procedures [4,6-9].
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